Home > Insider Trading > Filing (0001209191-24-001959)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1539029	Clearside Biomedical Inc.	CLSD	Pharmaceutical Preparations (2834)	452437375

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1664690	A. Charles Deignan	C/O Clearside Biomedical, Inc. 900 North Point Parkway, Suite 200 Alpharetta GA 30005	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2024-01-19	12,900	$1.28	384,662	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Acquisiton	2024-01-18	200,000	$0.00	200,000	$1.29

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
200,000		2034-01-18	No	4	A	Direct

Footnotes

The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.18 to $1.32 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
One-fourth of the shares underlying this option vest on January 18, 2025 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such vesting date.